HXR9

HXR9 is a cell-permeable, 18-amino-acid synthetic peptide designed to disrupt the interaction between HOX transcription factors and their PBX cofactors. Developed by researchers at the University of Surrey and the University of Bradford, and licensed to HOX Therapeutics, HXR9 acts as a competitive antagonist by mimicking the conserved hexapeptide sequence of HOX proteins (paralogue groups 1-9) that binds to the pocket of PBX proteins (PBX1, PBX2, PBX3, and PBX4). This disruption prevents the formation of active HOX/PBX dimers, thereby inhibiting their cooperative DNA binding and transcriptional activity. Consequently, HXR9 triggers apoptosis or necroptosis in a wide range of cancer cells, including breast cancer, prostate cancer, melanoma, ovarian cancer, non-small cell lung cancer, mesothelioma, renal cancer, and acute myeloid leukemia. HXR9 serves as the parent compound for next-generation clinical candidates, such as HTL-001.

Other names

HXR9 hydrochlorideHXR-9 hydrochlorideHXR 9 hydrochlorideHXR9 peptideHXR-9 peptideHXR 9 peptide